About Ted Fjallman
Form D filings for GENEOS Therapeutics from 2022 to 2023 list Ted Fjallman as director.
Ted Fjallman first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Ted Fjallman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Ted Fjallman works with at each company, as listed on that company's latest Form D.
GENEOS Therapeutics, Inc. · Form D, Apr 13, 2023
LH
Laurent Humeau
Director
JE
James Eadie
Director
NS
Niranjan Sardesai
Chief Executive Officer and director
SB
Samuel Broder
Director
SL
Sangwoo Lee
Director
CC
Casey Cunningham
Director